UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended July 3, 2022
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware13-5315170
(State of Incorporation)(I.R.S. Employer Identification No.)
235 East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $.05 par valuePFENew York Stock Exchange
1.000% Notes due 2027PFE27New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
YesxNo
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
YesxNo
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act:
Large Accelerated filer x Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes Nox
At August 5, 2022, 5,612,351,809 shares of the issuer s voting common stock were outstanding.
TABLE OF CONTENTS
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Income
Condensed Consolidated Statements of Comprehensive Income
Condensed Consolidated Balance Sheets
Condensed Consolidated Statements of Equity
Condensed Consolidated Statements of Cash Flows
Notes to Condensed Consolidated Financial Statements
10
Item 2.
Management s Discussion and Analysis of Financial Condition and Results of Operations
37
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
59
Item 4.
Controls and Procedures
59
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
59
Item 1A.
Risk Factors
59
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
59
Item 3.
Defaults Upon Senior SecuritiesN/A
Item 4.
Mine Safety DisclosuresN/A
Item 5.
Other InformationN/A
Item 6.
Exhibits
60
Signature
60
N/A = Not Applicable
DEFINED TERMS
Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and six months ended May 29, 2022 and May 30, 2021, and for U.S. subsidiaries is as of and for the three and six months ended July 3, 2022 and July 4, 2021. References to Notes in this Form 10-Q are to the Notes to the Condensed or Consolidated Financial Statements in this Form 10-Q or in our 2021 Form 10-K. We also have used several other terms in this Form 10-Q, most of which are explained or defined below:
2021 Form 10-KAnnual Report on Form 10-K for the fiscal year ended December 31, 2021
ACIPAdvisory Committee on Immunization Practices
ALKanaplastic lymphoma kinase
Alliance revenuesRevenues from alliance agreements under which we co-promote products discovered or developed by other companies or us
ArenaArena Pharmaceuticals, Inc.
AstellasAstellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.
ATTR-CMtransthyretin amyloid cardiomyopathy
BiohavenBiohaven Pharmaceutical Holding Company Ltd.
BioNTechBioNTech SE
BiopharmaPfizer Biopharmaceuticals Group
BLABiologics License Application
BMSBristol-Myers Squibb Company
BNT162b2*Pfizer-BioNTech COVID-19 Vaccine, also known as Comirnaty
BODBoard of Directors
CDCU.S. Centers for Disease Control and Prevention
CGRPcalcitonin gene-related peptide
CMAconditional marketing authorisation
Comirnaty*Pfizer-BioNTech COVID-19 Vaccine, also known as BNT162b2
Consumer Healthcare JVGSK Consumer Healthcare JV
COVID-19novel coronavirus disease of 2019
Developed EuropeIncludes the following markets: Western Europe, Scandinavian countries and Finland
Developed MarketsIncludes the following markets: U.S., Developed Europe, Japan, South Korea, Australia, Canada and New Zealand
Developed Rest of WorldIncludes the following markets: Japan, South Korea, Australia, Canada and New Zealand
ECEuropean Commission
EMAEuropean Medicines Agency
Emerging MarketsIncludes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Central Europe, Eastern Europe, the Middle East, Africa and Turkey
EPSearnings per share
EUEuropean Union
EUAemergency use authorization
Exchange ActSecurities Exchange Act of 1934, as amended
FDAU.S. Food and Drug Administration
FFDCAU.S. Federal Food, Drug and Cosmetic Act
Form 10-QThis Quarterly Report on Form 10-Q for the quarterly period ended July 3, 2022
GAAPGenerally Accepted Accounting Principles
GISTgastrointestinal stromal tumors
GPDGlobal Product Development organization
GSKGlaxoSmithKline plc
HaleonHaleon plc
HIPAAHealth Insurance Portability and Accountability Act of 1996
HospiraHospira, Inc.
IPR&Din-process research and development
IRSU.S. Internal Revenue Service
JAKJanus kinase
JVjoint venture
KingKing Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)
LIBORLondon Interbank Offered Rate
LOEloss of exclusivity
mCRCmetastatic colorectal cancer
mCRPCmetastatic castration-resistant prostate cancer
mCSPCmetastatic castration-sensitive prostate cancer
MD&AManagement s Discussion and Analysis of Financial Condition and Results of Operations
MeridianMeridian Medical Technologies, Inc.
mRNAmessenger ribonucleic acid
MSAManufacturing Supply Agreement
MylanMylan N.V.
MyovantMyovant Sciences Ltd.
NDANew Drug Application
nmCRPCnon-metastatic castration-resistant prostate cancer
NSCLCnon-small cell lung cancer
OPKOOPKO Health, Inc.
OTCover-the-counter
Paxlovid*an oral COVID-19 treatment (nirmatrelvir [PF-07321332] tablets and ritonavir tablets)
PC1Pfizer CentreOne
PGSPfizer Global Supply
PharmaciaPharmacia Corporation
PRACPharmacovigilance Risk Assessment Committee
PsApsoriatic arthritis
QTDQuarter-to-date or three months ended
RArheumatoid arthritis
RCCrenal cell carcinoma
R&Dresearch and development
ReViralReViral Ltd.
SandozSandoz, Inc., a division of Novartis AG
SECU.S. Securities and Exchange Commission
sNDAsupplemental new drug application
TSAstransition service arrangements
UCulcerative colitis
U.K.United Kingdom
U.S.United States
Upjohn BusinessPfizer s former global, primarily off-patent branded and generics business, which included a portfolio of 20 globally recognized solid oral dose brands, including Lipitor, Lyrica, Norvasc, Celebrex and Viagra, as well as a U.S.-based generics platform, Greenstone, that was spun-off on November 16, 2020 and combined with Mylan to create Viatris
ViatrisViatris Inc.
ViiVViiV Healthcare Limited
WRDMWorldwide Research, Development and Medical
YTDYear-to-date or six months ended
*This Form 10-Q includes discussion of the COVID-19 vaccine that Pfizer has co-developed with BioNTech (BNT162b2) and our oral COVID-19 treatment (Paxlovid). The vaccine may be referred to by its brand name, Comirnaty (approved under a BLA in the U.S.), or as BNT162b2 (authorized under EUA in the U.S.). The vaccine is FDA-approved to prevent COVID-19 in individuals 12 years of age and older. In addition, Comirnaty/BNT162b2 is authorized for emergency use by the FDA for individuals 6 months of age and older, as a third dose for certain immunocompromised individuals 5 years of age and older, as a booster dose for individuals 5 years of age and older and as a second booster dose for individuals 50 years of age and older and for certain immunocompromised individuals 12 years of age and older. Paxlovid is authorized for emergency use by the FDA under an EUA for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg [88 lbs]) with positive results of direct SARS CoV-2 viral testing, and who are at high-risk for progression to severe COVID-19, including hospitalization or death. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FFDCA unless the declaration is terminated or authorization revoked sooner. The FDA has issued EUAs to certain other companies for products intended for the prevention or treatment of COVID-19 and may continue to do so during the duration of the Declaration. See the EUA Fact Sheets at www.cvdvaccine-us.com and www.covid19oralrx.com.
This Form 10-Q includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.
Some amounts in this Form 10-Q may not add due to rounding. All percentages have been calculated using unrounded amounts. All trademarks mentioned are the property of their owners.
The information contained on our website, our Facebook, Instagram, YouTube and LinkedIn pages or our Twitter accounts, or any third-party website, is not incorporated by reference into this Form 10-Q.
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months EndedSix Months Ended
(MILLIONS, EXCEPT PER COMMON SHARE DATA)July 3,
2022July 4,
2021July 3,
2022July 4,
2021
Revenues$27,742 $18,899 $53,402 $33,415
Costs and expenses:
Cost of sales(a)
8,648 6,996 18,632 11,153
Selling, informational and administrative expenses(a)
3,048 2,923 5,642 5,700
Research and development expenses(a)
2,815 2,239 5,116 4,233
Acquired in-process research and development expenses(b)
1 219 356 238
Amortization of intangible assets822 917 1,657 1,776
Restructuring charges and certain acquisition-related costs189 (1)381 21
Other (income)/deductions net772 (1,343)1,122 (2,347)
Income from continuing operations before provision/(benefit) for taxes on income11,447 6,949 20,497 12,641
Provision/(benefit) for taxes on income1,570 1,123 2,742 1,931
Income from continuing operations9,877 5,825 17,756 10,710
Discontinued operations net of tax34 (236)26 (235)
Net income before allocation to noncontrolling interests9,911 5,589 17,781 10,475
Less: Net income attributable to noncontrolling interests6 26 12 35
Net income attributable to Pfizer Inc. common shareholders$9,906 $5,563 $17,769 $10,440
Earnings per common share basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders$1.76 $1.04 $3.17 $1.91
Discontinued operations net of tax0.01 (0.04) (0.04)
Net income attributable to Pfizer Inc. common shareholders$1.77 $0.99 $3.17 $1.87
Earnings per common share diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders$1.73 $1.02 $3.09 $1.88
Discontinued operations net of tax0.01 (0.04) (0.04)
Net income attributable to Pfizer Inc. common shareholders$1.73 $0.98 $3.10 $1.84
Weighted-average shares basic5,593 5,598 5,605 5,591
Weighted-average shares diluted5,712 5,678 5,735 5,670
(a)Exclusive of amortization of intangible assets.
(b)See Note 1D.
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
Three Months EndedSix Months Ended
(MILLIONS)July 3,
2022July 4,
2021July 3,
2022July 4,
2021
Net income before allocation to noncontrolling interests$9,911 $5,589 $17,781 $10,475
Foreign currency translation adjustments, net(1,268)36 (1,631)501
Unrealized holding gains/(losses) on derivative financial instruments, net651 (248)854 (35)
Reclassification adjustments for (gains)/losses included in net income(a)
(144)(21)(357)238
507 (270)497 203
Unrealized holding gains/(losses) on available-for-sale securities, net(486)59 (620)138
Reclassification adjustments for (gains)/losses included in net income(b)
255 61 487 (181)
(232)120 (132)(43)
Reclassification adjustments related to amortization of prior service costs and other, net(31)(39)(68)(79)
Reclassification adjustments related to curtailments of prior service costs and other, net1 (1)(10)(5)
(30)(41)(78)(84)
Other comprehensive income/(loss), before tax(1,023)(155)(1,344)577
Tax provision/(benefit) on other comprehensive income/(loss)(55)(63)(115)21
Other comprehensive income/(loss) before allocation to noncontrolling interests$(968)$(92)$(1,228)$556
Comprehensive income/(loss) before allocation to noncontrolling interests$8,943 $5,498 $16,553 $11,031
Less: Comprehensive income/(loss) attributable to noncontrolling interests 28 6 38
Comprehensive income/(loss) attributable to Pfizer Inc.$8,943 $5,469 $16,546 $10,992
(a)Reclassified into Other (income)/deductions net and Cost of sales. See Note 7E.
(b)Reclassified into Other (income)/deductions net.
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(MILLIONS)July 3,
2022December 31, 2021
(Unaudited)
Assets
Cash and cash equivalents$1,780 $1,944
Short-term investments31,524 29,125
Trade accounts receivable, less allowance for doubtful accounts: 2022 $461; 2021 $492
15,155 11,479
Inventories10,454 9,059
Current tax assets2,583 4,266
Other current assets5,970 3,820
Total current assets67,466 59,693
Equity-method investments14,799 16,472
Long-term investments4,163 5,054
Property, plant and equipment, less accumulated depreciation: 2022 $14,969; 2021 $15,074
15,244 14,882
Identifiable intangible assets29,065 25,146
Goodwill49,891 49,208
Noncurrent deferred tax assets and other noncurrent tax assets7,002 3,341
Other noncurrent assets7,659 7,679
Total assets$195,290 $181,476
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2022 $1,276; 2021 $1,636
$5,990 $2,241
Trade accounts payable6,208 5,578
Dividends payable2,245 2,249
Income taxes payable3,350 1,266
Accrued compensation and related items1,997 3,332
Deferred revenues3,804 3,067
Other current liabilities23,816 24,939
Total current liabilities47,410 42,671
Long-term debt34,294 36,195
Pension benefit obligations3,030 3,489
Postretirement benefit obligations227 235
Noncurrent deferred tax liabilities558 349
Other taxes payable10,990 11,331
Other noncurrent liabilities11,311 9,743
Total liabilities107,821 104,013
Commitments and Contingencies
Common stock476 473
Additional paid-in capital91,183 90,591
Treasury stock(113,939)(111,361)
Retained earnings116,608 103,394
Accumulated other comprehensive loss(7,119)(5,897)
Total Pfizer Inc. shareholders equity87,208 77,201
Equity attributable to noncontrolling interests261 262
Total equity87,469 77,462
Total liabilities and equity$195,290 $181,476
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(UNAUDITED)
PFIZER INC. SHAREHOLDERS
Common StockTreasury Stock
(MILLIONS, EXCEPT PER COMMON SHARE DATA)SharesPar ValueAdd l
Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.
LossShare-
holders EquityNon-controlling interestsTotal Equity
Balance, April 3, 2022
9,494 $476 $90,844 (3,903)$(113,931)$111,193 $(6,157)$82,424 $261 $82,685
Net income9,906 9,906 6 9,911
Other comprehensive income/(loss), net of tax
(963)(963)(5)(968)
Cash dividends declared, per share: $0.80
Common stock(4,489)(4,489)(4,489)
Share-based payment transactions2 339 (8)(2)330 330
Purchases of common stock
Other
Balance, July 3, 2022
9,496 $476 $91,183 (3,903)$(113,939)$116,608 $(7,119)$87,208 $261 $87,469
PFIZER INC. SHAREHOLDERS
Common StockTreasury Stock
(MILLIONS, EXCEPT PER COMMON SHARE DATA)SharesPar ValueAdd l
Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.
LossShare-
holders EquityNon-controlling interestsTotal Equity
Balance, April 4, 2021
9,445 $472 $89,002 (3,851)$(111,349)$95,158 $(4,664)$68,620 $245 $68,865
Net income5,563 5,563 26 5,589
Other comprehensive income/(loss), net of tax(94)(94)2 (92)
Cash dividends declared, per share: $0.78
Common stock (4,293)(4,293)(4,293)
Share-based payment transactions5 334 (7)(76)251 251
Purchases of common stock
Other (7)(6) (6)
Balance, July 4, 2021
9,450 $472 $89,336 (3,851)$(111,356)$96,346 $(4,758)$70,042 $273 $70,315
PFIZER INC. SHAREHOLDERS
Common StockTreasury Stock
(MILLIONS, EXCEPT PER COMMON SHARE DATA)SharesPar ValueAdd l
Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.
LossShare-
holders EquityNon-controlling interestsTotal Equity
Balance, January 1, 2022
9,471 $473 $90,591 (3,851)$(111,361)$103,394 $(5,897)$77,201 $262 $77,462
Net income17,769 17,769 12 17,781
Other comprehensive income/(loss), net of tax(1,223)(1,223)(6)(1,228)
Cash dividends declared, per share: $0.80
Common stock(4,489)(4,489)(4,489)
Share-based payment transactions25 2 588 (12)(578)(66)(53)(53)
Purchases of common stock(39)(2,000)(2,000)(2,000)
Other3 3 (7)(4)
Balance, July 3, 2022
9,496 $476 $91,183 (3,903)$(113,939)$116,608 $(7,119)$87,208 $261 $87,469
PFIZER INC. SHAREHOLDERS
Common StockTreasury Stock
(MILLIONS, EXCEPT PER COMMON SHARE DATA)SharesPar ValueAdd l
Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.
LossShare-
holders EquityNon-controlling interestsTotal Equity
Balance, January 1, 2021
9,407 $470 $88,674 (3,840)$(110,988)$90,392 $(5,310)$63,238 $235 $63,473
Net income10,440 10,440 35 10,475
Other comprehensive income/(loss), net of tax552 552 3 556
Cash dividends declared, per share: $0.78
Common stock (4,377)(4,377)(4,377)
Share-based payment transactions43 2 662 (11)(368)(76)221 221
Purchases of common stock
Other (33)(33) (33)
Balance, July 4, 2021
9,450 $472 $89,336 (3,851)$(111,356)$96,346 $(4,758)$70,042 $273 $70,315
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Six Months Ended
(MILLIONS)July 3,
2022July 4,
2021
Operating Activities
Net income before allocation to noncontrolling interests$17,781 $10,475
Discontinued operations net of tax26 (235)
Net income from continuing operations before allocation to noncontrolling interests17,756 10,710
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization2,362 2,515
Asset write-offs and impairments58 55
Deferred taxes from continuing operations(3,461)137
Share-based compensation expense373 393
Benefit plan contributions in excess of expense/income(146)(779)
Other adjustments, net1,270 (1,305)
Other changes in assets and liabilities, net of acquisitions and divestitures(3,496)4,102
Net cash provided by operating activities from continuing operations14,717 15,828
Net cash provided by/(used in) operating activities from discontinued operations(5)9
Net cash provided by operating activities14,711 15,837
Investing Activities
Purchases of property, plant and equipment(1,394)(1,091)
Purchases of short-term investments(18,937)(15,982)
Proceeds from redemptions/sales of short-term investments20,151 7,572
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less(3,153)(505)
Purchases of long-term investments(1,324)(100)
Proceeds from redemptions/sales of long-term investments226 297
Acquisition of business, net of cash acquired(6,225)
Other investing activities, net(91)(72)
Net cash provided by/(used in) investing activities from continuing operations(10,746)(9,880)
Net cash provided by/(used in) investing activities from discontinued operations (3)
Net cash provided by/(used in) investing activities(10,746)(9,884)
Financing Activities
Proceeds from short-term borrowings4,012
Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less
379 (499)
Principal payments on long-term debt(1,609)
Purchases of common stock(2,000)
Cash dividends paid(4,493)(4,355)
Other financing activities, net(347)(509)
Net cash provided by/(used in) financing activities(4,058)(5,364)
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents
(67)5
Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents(159)593
Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period1,983 1,825
Cash and cash equivalents and restricted cash and cash equivalents, at end of period$1,824 $2,418
Supplemental Cash Flow Information
Cash paid/(received) during the period for:
Income taxes
$3,098 $2,188
Interest paid
771 798
Interest rate hedges(10)(67)
Non-cash transaction:
Right-of-use assets obtained in exchange for lease liabilities$242 $1,204
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of Presentation and Significant Accounting Policies
A. Basis of Presentation
We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2021 Form 10-K. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.
These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2021 Form 10-K. Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and six months ended May 29, 2022 and May 30, 2021, and for U.S. subsidiaries is as of and for the three and six months ended July 3, 2022 and July 4, 2021.
At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business, and PC1, our global contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients. Biopharma is the only reportable segment. See Note 17A in our 2021 Form 10-K and Note 13 below.
Business development activities completed in 2021 and 2022 impacted financial results in the periods presented. Discontinued operations in the periods presented relate to the previously divested Meridian subsidiary and post-closing adjustments for other previously divested businesses. See Notes 1A and 2B in our 2021 Form 10-K, and Note 2B below.
We have made certain reclassification adjustments to conform prior-period amounts to the current presentation for discontinued operations, acquired IPR&D expenses and segment reporting.
B. New Accounting Standard Adopted in 2022
On January 1, 2022, we early adopted a new accounting standard for contract assets and contract liabilities acquired in a business combination. Under the new standard, acquired contract assets and contract liabilities are required to be recognized and measured by the acquirer on the acquisition date in accordance with Accounting Standards Codification 606. This new guidance generally results in the acquirer recognizing contract assets and contract liabilities at the same amounts that were recorded by the acquiree. Previously, these amounts were recognized by the acquirer at fair value as of the acquisition date. We adopted this new standard on a prospective basis and there was no impact to our consolidated financial statements.
C. Revenues and Trade Accounts Receivable
Revenue Recognition We record revenues from product sales when there is a transfer of control of the product from us to the customer. We typically determine transfer of control based on when the product is shipped or delivered and title passes to the customer. For certain contracts, the finished product may temporarily be stored at our or our third-party subcontractors locations under a bill-and-hold arrangement. Revenue is recognized on bill-and-hold arrangements at the point in time when the customer obtains control of the product and all of the following criteria have been met: the arrangement is substantive; the product is identified separately as belonging to the customer; the product is ready for physical transfer to the customer; and we do not have the ability to use the product or direct it to another customer. In determining when the customer obtains control of the product, we consider certain indicators, including whether we have a present right to payment from the customer, whether title and/or significant risks and rewards of ownership have transferred to the customer and whether customer acceptance has been received.
Customers Our prescription pharmaceutical products, with the exception of Paxlovid, are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. We principally sell Paxlovid to government agencies. In the U.S., we primarily sell our vaccine products directly to the federal government, CDC, wholesalers, individual provider offices, retail pharmacies and integrated delivery networks. Outside the U.S., we primarily sell our vaccines to government and non-government institutions.
10
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Deductions from Revenues Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:
(MILLIONS)July 3,
2022December 31, 2021
Reserve against Trade accounts receivable, less allowance for doubtful accounts
$1,057 $1,077
Other current liabilities:
Accrued rebates3,875 3,811
Other accruals458 528
Other noncurrent liabilities
386 433
Total accrued rebates and other sales-related accruals$5,776 $5,850
Trade Accounts Receivable Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables.
In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.
During the three and six months ended July 3, 2022 and July 4, 2021, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements. For additional information on our trade accounts receivable, see Note 1H in our 2021 Form 10-K.
D. Acquired In-Process Research and Development Expenses
In the first quarter of 2022, we began reporting acquired IPR&D expense as a separate line item in our consolidated statements of income. Acquired in-process research and development expenses includes costs incurred in connection with (a) all upfront and milestone payments on collaboration and in-license agreements, including premiums on equity securities and (b) asset acquisitions of acquired IPR&D. These costs were previously recorded in Research and development expenses. Prior periods have been revised to conform to the current period presentation. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&D is expensed. The fair value of IPR&D acquired in connection with a business combination is recorded on the balance sheet as Identifiable intangible assets. See Notes 1E and 10 in our 2021 Form 10-K.
Note 2. Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement
A. Acquisition
Arena On March 11, 2022, we acquired Arena, a clinical stage company, for $100 per share in cash. The total fair value of the consideration transferred was $6.6 billion ($6.2 billion, net of cash acquired). In addition, $138 million in payments to Arena employees for the fair value of previously unvested long-term incentive awards was recognized as post-closing compensation expense and recorded in Restructuring charges and certain acquisition-related costs (see Note 3).
Arena s portfolio includes development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator currently in development for a range of immuno-inflammatory diseases including UC, Crohn s disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata. In connection with this acquisition, we provisionally recorded: (i) $5.5 billion in Identifiable intangible assets, consisting of $5.0 billion of IPR&D and $460 million of indefinite-lived Licensing agreements and other, (ii) $1.0 billion of Goodwill and (iii) $510 million of net deferred tax liabilities. The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not yet been finalized.
11
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
B. Discontinued Operations
Meridian On December 31, 2021, we completed the sale of our Meridian subsidiary. In the three and six months ended July 3, 2022, the amounts recorded under the interim TSAs and MSA were not material.
Upjohn Separation and Combination with Mylan On November 16, 2020, we completed the spin-off and the combination of the Upjohn Business with Mylan to form Viatris. In connection with this transaction, Pfizer and Viatris entered into various agreements to effect the separation and combination and to provide a framework for our relationship after the combination, including a separation and distribution agreement, interim operating models, including agency arrangements, MSAs, TSAs, a tax matters agreement, and an employee matters agreement, among others. The amounts recorded under these agreements were not material to our consolidated results of operations in the three and six months ended July 3, 2022 and July 4, 2021. Net amounts due from Viatris under the agreements were approximately $272 million as of July 3, 2022 and $53 million as of December 31, 2021. The cash flows associated with the agreements are included in Net cash provided by operating activities from continuing operations, except for a $277 million payment to Viatris made in the first quarter of 2021 pursuant to terms of the separation agreement, which is reported in Other financing activities, net.
Discontinued operations net of tax for the three and six months ended July 4, 2021 reflects pre-tax loss from discontinued operations of $346 million and $337 million, respectively, and primarily includes pre-disposal operations related to our former Meridian subsidiary including a $345 million pre-tax expense to resolve a Multi-District Litigation relating to EpiPen against the Company in the U.S. District Court for the District of Kansas (prior to presenting Meridian as discontinued operations, this EpiPen litigation amount was included in Other (income)/deductions net). For the three and six months ended July 3, 2022, Discontinued operations net of tax reflects pre-tax income from discontinued operations of $34 million and $24 million, respectively, and relates to post-closing adjustments for previously divested businesses primarily for tax and legal matters.
C. Equity-Method Investment
Consumer Healthcare JV On July 31, 2019, we completed a transaction in which we and GSK combined our respective consumer healthcare businesses into a new JV that operated globally under the GSK Consumer Healthcare name. In exchange for the contribution of our consumer healthcare business to the JV, we received a 32% equity stake in the new company and GSK owned the remaining 68%. We have accounted for our interest in the Consumer Healthcare JV as an equity-method investment. The carrying value of our investment in the Consumer Healthcare JV is $14.6 billion as of July 3, 2022 and $16.3 billion as of December 31, 2021 and is reported as a private equity investment in Equity-method investments as of July 3, 2022 and December 31, 2021. The Consumer Healthcare JV is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in other comprehensive income. The decrease in the value of our investment from December 31, 2021 is primarily due to $1.7 billion in pre-tax foreign currency translation adjustments (see Note 6), as well as dividends totaling approximately $354 million, partially offset by our share of the JV s earnings. We record our share of earnings from the Consumer Healthcare JV on a quarterly basis on a one-quarter lag in Other (income)/deductions net. Our total share of the JV s earnings generated in the first quarter of 2022, which we recorded in our operating results in the second quarter of 2022, was $150 million. Our total share of the JV s earnings generated in the fourth quarter of 2021 and first quarter of 2022, which we recorded in our operating results in the first six months of 2022, was $335 million. Our total share of the JV s earnings generated in the first quarter of 2021, which we recorded in our operating results in the second quarter of 2021, was $148 million. Our total share of the JV s earnings generated in the fourth quarter of 2020 and first quarter of 2021, which we recorded in our operating results in the first six months of 2021, was $218 million. The total amortization and adjustment of basis differences resulting from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the JV is included in Other (income)/deductions net and was not material to our results of operations in the periods presented. See Note 4.
12
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Summarized financial information for our equity method investee, the Consumer Healthcare JV, for the three and six months ending March 31, 2022, the most recent period available, and for the three and six months ending March 31, 2021, is as follows:
Three Months EndedSix Months Ended
(MILLIONS)March 31,
2022March 31,
2021March 31,
2022March 31,
2021
Net sales$3,526 $3,180 $6,945 $6,275
Cost of sales(1,322)(1,169)(2,634)(2,356)
Gross profit$2,204 $2,011 $4,312 $3,919
Income from continuing operations487 483 1,077 716
Net income487 483 1,077 716
Income attributable to shareholders468 461 1,046 682
In connection with GSK s previously announced planned demerger of at least 80% of GSK s 68% equity interest in the Consumer Healthcare JV, in March 2022 the Consumer Healthcare JV completed its offering of a total aggregate principal amount of $8.75 billion in U.S. dollar-denominated senior notes of various maturities, 2.35 billion in euro-denominated senior notes of various maturities and 700 million in U.K. pound-denominated senior notes of various maturities (collectively, the notes ). The notes were guaranteed by GSK generally up to and excluding the date of the demerger (the Guarantee Assumption Date ). We agreed to indemnify GSK for 32% (representing our pro rata equity interest in the Consumer Healthcare JV) of any amount payable by GSK pursuant to its guarantee of the notes. Our indemnity was provided solely for the benefit of GSK. Neither we nor any of our subsidiaries is an issuer or guarantor of any of the notes.
Following its issuance of the notes in March 2022, which fell in our international second quarter of 2022, the Consumer Healthcare JV loaned to us and GSK the net proceeds received from the notes on a pro rata equity ownership basis, for which we received a loan of 2.9 billion ($3.7 billion as of the end of our second quarter of 2022), at an interest rate of 1.365% per annum payable semi-annually in arrears.
On July 18, 2022, GSK completed its demerger of the Consumer Healthcare JV which became Haleon, an independent, publicly traded company listed on the London Stock Exchange that holds the joint Consumer Healthcare business of GSK and Pfizer following the demerger. In conjunction with the demerger, we received 3.5 billion ($4.2 billion) in dividends from the JV in July 2022, which decreased the carrying value of our investment. Simultaneous with the receipt of the dividends, we repaid the loan from the JV. GSK similarly received pro rata dividends and simultaneously repaid its pro rata loan from the JV. In conjunction with these transactions, our indemnification of GSK s guarantee discussed above was terminated. We continue to own 32% of Haleon after the transactions related to the demerger and continue to account for our interest in Haleon as an equity-method investment.
D. Collaborative Arrangement
Collaboration with Biohaven In November 2021, we entered into a collaboration and license agreement and related sublicense agreement with Biohaven and certain of its subsidiaries to commercialize rimegepant and zavegepant for the treatment and prevention of migraines outside of the U.S., subject to regulatory approval. Biohaven will continue to lead R&D globally and we have the exclusive right to commercialization globally, outside of the U.S. Upon the closing of the transaction on January 4, 2022, we paid Biohaven $500 million, including an upfront payment of $150 million and an equity investment of $350 million. We recognized $263 million for the upfront payment and premium paid on our equity investment in Acquired in-process research and development expenses. Biohaven is also eligible to receive up to $740 million in non-U.S. commercialization milestone payments, in addition to tiered double-digit royalties on net sales outside of the U.S. In addition to the milestone payments and royalties above, we will also reimburse Biohaven for the portion of certain additional milestone payments and royalties due to third parties in accordance with preexisting Biohaven agreements, which are attributed to ex-U.S. sales.
Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
A. Transforming to a More Focused Company Program
With the formation of the Consumer Healthcare JV in 2019 and the spin-off of our Upjohn Business in the fourth quarter of 2020, Pfizer has transformed into a focused, global leader in science-based innovative medicines and vaccines. We continue our efforts to ensure our cost base and support model align appropriately with this operating structure. While certain direct costs
13
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
transferred to the Consumer Healthcare JV, and to the Upjohn Business in connection with the spin-off, there are indirect costs which did not transfer. This program is primarily composed of the following three initiatives:
We are taking steps to restructure our corporate enabling functions to appropriately support our business, R&D and PGS platform functions. We expect costs, primarily related to restructuring our corporate enabling functions, to total $1.8 billion, with substantially all costs to be cash expenditures. Actions include, among others, changes in location of certain activities, expanded use and co-location of centers of excellence and shared services, and increased use of digital technologies. The associated actions and the specific costs primarily include severance and benefit plan impacts, exit costs as well as associated implementation costs.
In addition, we are transforming our commercial go-to market model in the way we engage patients and physicians. We expect costs of $1.2 billion, with all costs to be cash expenditures. Actions include, among others, centralization of certain activities and enhanced use of digital technologies. The costs for this effort primarily include severance and associated implementation costs.
We are also optimizing our manufacturing network under this program and incurring one-time costs for cost-reduction initiatives related to our manufacturing operations. We expect to incur costs of $800 million, with approximately 25% of the costs to be non-cash. The costs for this effort include, among other things, severance costs, implementation costs, product transfer costs, site exit costs, as well as accelerated depreciation.
The program costs discussed above are expected to be incurred primarily from 2020 through 2022, and may be rounded and represent approximations.
From the start of this program in the fourth quarter of 2019 through July 3, 2022, we incurred costs of $2.5 billion, of which $987 million ($800 million of restructuring charges) is associated with Biopharma.
B. Key Activities
The following summarizes acquisitions and cost-reduction/productivity initiatives costs and credits:
Three Months EndedSix Months Ended
(MILLIONS)July 3,
2022July 4,
2021July 3,
2022July 4,
2021
Restructuring charges/(credits):
Employee terminations$110 $(4)$135 $19
Asset impairments20 2 28 (3)
Exit costs/(credits)18 (3)29 (3)
Restructuring charges/(credits)(a)
147 (5)191 12
Transaction costs(b)
36 42
Integration costs and other(c)
6 4 148 8
Restructuring charges and certain acquisition-related costs189 (1)381 21
Net periodic benefit costs/(credits) recorded in Other (income)/deductions net
4 (6)12
Additional depreciation asset restructuring recorded in our condensed consolidated statements of income as follows(d):
Cost of sales7 27 15 34
Selling, informational and administrative expenses 16 16
Total additional depreciation asset restructuring7 43 15 49
Implementation costs recorded in our condensed consolidated statements of income as follows(e):
Cost of sales15 10 27 21
Selling, informational and administrative expenses134 80 208 144
Total implementation costs149 90 235 166
Total costs associated with acquisitions and cost-reduction/productivity initiatives$345 $137 $625 $248
(a)Primarily represents cost reduction initiatives. Restructuring charges/(credits) associated with Biopharma: charges of $50 million and $46 million for the three and six months ended July 3, 2022, respectively, and credits of $4 million and charges of $1 million for the three and six months ended July 4, 2021, respectively.
(b)Represents external costs for banking, legal, accounting and other similar services.
14
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(c)Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the three and six months ended July 3, 2022, integration costs and other were mostly related to our acquisition of Arena, including $138 million in payments to Arena employees in the first quarter of 2022 for the fair value of previously unvested long-term incentive awards. See Note 2A.
(d)Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
(e)Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
The following summarizes the components and changes in restructuring accruals:
(MILLIONS)Employee
Termination
CostsAsset
Impairment
ChargesExit CostsAccrual
Balance, December 31, 2021(a)
$1,014 $ $57 $1,071
Provision135 28 29 191
Utilization and other(b)
(244)(28)(78)(349)
Balance, July 3, 2022(c)
$904 $ $8 $913
(a)Included in Other current liabilities ($816 million) and Other noncurrent liabilities ($255 million).
(b)Includes adjustments for foreign currency translation.
(c)Included in Other current liabilities ($794 million) and Other noncurrent liabilities ($119 million).
Note 4. Other (Income)/Deductions Net
Components of Other (income)/deductions net include:
Three Months EndedSix Months Ended
(MILLIONS)July 3,
2022July 4,
2021July 3,
2022July 4,
2021
Interest income$(30)$(13)$(44)$(12)
Interest expense293 316 614 651
Net interest expense263 303 571 639
Royalty-related income(217)(212)(389)(388)
Net (gains)/losses on asset disposals (58)(1)(98)
Net (gains)/losses recognized during the period on equity securities(a)
541 (800)1,241 (1,200)
Income from collaborations, out-licensing arrangements and sales of compound/product rights(b)
(5)(21)(14)(252)
Net periodic benefit costs/(credits) other than service costs295 (237)12 (503)
Certain legal matters, net19 24 98 74
Consumer Healthcare JV equity method (income)/loss(c)
(149)(140)(334)(202)
Other, net26 (201)(62)(417)
Other (income)/deductions net$772 $(1,343)$1,122 $(2,347)
(a)The losses in the second quarter and first six months of 2022 include, among other things, unrealized losses of $432 million and $776 million, respectively, related to investments in BioNTech and Cerevel Therapeutics Holdings, Inc. (Cerevel). The gains in the second quarter and first six months of 2021 included, among other things, unrealized gains of $917 million and $1.0 billion, respectively, related to investments in BioNTech and Cerevel.
(b)The first six months of 2021 included, among other things, $188 million of net collaboration income from BioNTech in the first quarter of 2021 related to Comirnaty.
(c)See Note 2C.
Note 5. Tax Matters
A. Taxes on Income from Continuing Operations
Our effective tax rate for continuing operations was 13.7% for the second quarter of 2022, compared to 16.2% for the second quarter of 2021, and was 13.4% for the first six months of 2022, compared to 15.3% for the first six months of 2021. The lower effective tax rates for the second quarter and first six months of 2022, compared to the second quarter and first six months of 2021, were primarily due to the favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business.
We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings over eight years through 2026. The fourth annual installment of this liability was paid by its April 18, 2022 due date. The fifth annual installment is due April 18, 2023 and is reported in current Income taxes payable as of July 3, 2022. The remaining liability is reported in noncurrent Other taxes
15
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
payable. Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.
B. Tax Contingencies
We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation.
The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. With respect to Pfizer, the IRS has issued Revenue Agent s Reports (RARs) for tax years 2011-2013 and 2014-2015. We are not in agreement with the RARs and are currently appealing certain disputed issues. Tax years 2016-2018 are currently under audit. Tax years 2019-2022 are open but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years in certain major international tax jurisdictions dating back to 2011.
For additional information, see Note 5D in our 2021 Form 10-K.
C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)
Components of Tax provision/(benefit) on other comprehensive income/(loss) include:
Three Months EndedSix Months Ended
(MILLIONS)July 3,
2022July 4,
2021July 3,
2022July 4,
2021
Foreign currency translation adjustments, net(a)
$(114)$(19)$(185)$2
Unrealized holding gains/(losses) on derivative financial instruments, net98 (51)130 7
Reclassification adjustments for (gains)/losses included in net income(3)1 (26)35
95 (50)105 43
Unrealized holding gains/(losses) on available-for-sale securities, net(61)7 (78)17
Reclassification adjustments for (gains)/losses included in net income32 8 61 (23)
(29)15 (17)(5)
Reclassification adjustments related to amortization of prior service costs and other, net(7)(8)(16)(17)
Reclassification adjustments related to curtailments of prior service costs and other, net (1)(2)(1)
(8)(8)(18)(18)
Tax provision/(benefit) on other comprehensive income/(loss)$(55)$(63)$(115)$21
(a)Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.
Note 6. Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests
The following summarizes the changes, net of tax, in Accumulated other comprehensive loss:
Net Unrealized Gains/(Losses)Benefit Plans
(MILLIONS)Foreign Currency Translation Adjustments Derivative Financial InstrumentsAvailable-For-Sale SecuritiesPrior Service (Costs)/Credits and OtherAccumulated Other Comprehensive Income/(Loss)
Balance, December 31, 2021
$(6,172)$119 $(220)$377 $(5,897)
Other comprehensive income/(loss)(a)
(1,440)392 (116)(59)(1,223)
Balance, July 3, 2022$(7,612)$511 $(336)$318 $(7,119)
(a)Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments include net losses related to our equity method investment in the Consumer Healthcare JV (see Note 2C) and the impact of our net investment hedging program.
16
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 7. Financial Instruments
A. Fair Value Measurements
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:
July 3, 2022December 31, 2021
(MILLIONS)TotalLevel 1Level 2TotalLevel 1Level 2
Financial assets:
Short-term investments
Equity securities with readily determinable fair values:
Money market funds$4,373 $ $4,373 $5,365 $ $5,365
Available-for-sale debt securities:
Government and agency non-U.S.
21,758 21,758 17,318 17,318
Government and agency U.S.
2,839 2,839 4,050 4,050
Corporate and other
1,024 1,024 647 647
25,621 25,621 22,014 22,014
Total short-term investments29,994 29,994 27,379 27,379
Other current assets
Derivative assets:
Interest rate contracts
8 8 4 4
Foreign exchange contracts
1,322 1,322 704 704
Total other current assets1,331 1,331 709 709
Long-term investments
Equity securities with readily determinable fair values(a)
3,041 3,028 13 3,876 3,849 27
Available-for-sale debt securities:
Government and agency non-U.S.
305 305 465 465
Government and agency U.S.
6 6
Corporate and other
74 74 50 50
379 379 521 521
Total long-term investments3,420 3,028 392 4,397 3,849 548
Other noncurrent assets
Derivative assets:
Interest rate contracts
16 16
Foreign exchange contracts
562 562 242 242
Total derivative assets562 562 259 259
Insurance contracts(b)
665 665 808 808
Total other noncurrent assets1,227 1,227 1,067 1,067
Total assets$35,972 $3,028 $32,944 $33,552 $3,849 $29,703
Financial liabilities:
Other current liabilities
Derivative liabilities:
Foreign exchange contracts
$432 $ $432 $476 $ $476
Total other current liabilities432 432 476 476
Other noncurrent liabilities
Derivative liabilities:
Interest rate contracts206 206
Foreign exchange contracts
653 653 405 405
Total other noncurrent liabilities859 859 405 405
Total liabilities$1,291 $ $1,291 $881 $ $881
(a)Long-term equity securities of $144 million as of July 3, 2022 and $194 million as of December 31, 2021 were held in restricted trusts for U.S. non-qualified employee benefit plans.
(b)Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions net (see Note 4).
17
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis The carrying value of Long-term debt, excluding the current portion was $34 billion as of July 3, 2022 and $36 billion as of December 31, 2021. The estimated fair value of such debt, using a market approach and Level 2 inputs, was $34 billion as of July 3, 2022 and $42 billion as of December 31, 2021.
The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant as of July 3, 2022 and December 31, 2021. The fair value measurements of our held-to-maturity debt securities and short-term borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.
B. Investments
Total Short-Term, Long-Term and Equity-Method Investments
The following summarizes our investments by classification type:
(MILLIONS)July 3, 2022December 31, 2021
Short-term investments
Equity securities with readily determinable fair values(a)
$4,373 $5,365
Available-for-sale debt securities25,621 22,014
Held-to-maturity debt securities1,530 1,746
Total Short-term investments$31,524 $29,125
Long-term investments
Equity securities with readily determinable fair values$3,041 $3,876
Available-for-sale debt securities379 521
Held-to-maturity debt securities39 34
Private equity securities at cost(b)
705 623
Total Long-term investments$4,163 $5,054
Equity-method investments14,799 16,472
Total long-term investments and equity-method investments$18,962 $21,526
Held-to-maturity cash equivalents$225 $268
(a)As of July 3, 2022 and December 31, 2021, includes money market funds primarily invested in U.S. Treasury and government debt.
(b)Represent investments in the life sciences sector.
Debt Securities
At July 3, 2022, our investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:
July 3, 2022December 31, 2021
Gross UnrealizedMaturities (in Years)Gross Unrealized
(MILLIONS)Amortized CostGainsLossesFair ValueWithin 1Over 1
to 5Over 5Amortized CostGainsLossesFair Value
Available-for-sale debt securities
Government and agency non-U.S.
$22,445 $36 $(419)$22,062 $21,758 $305 $ $18,032 $13 $(263)$17,783
Government and agency U.S.
2,840 (1)2,839 2,839 4,056 (1)4,055
Corporate and other1,098 2 (2)1,098 1,024 74 698 (1)697
Held-to-maturity debt securities
Time deposits and other
913 913 878 23 11 947 947
Government and agency non-U.S.
881 881 876 3 1 1,102 1,102
Total debt securities$28,177 $38 $(422)$27,794 $27,376 $406 $12 $24,835 $14 $(265)$24,584
Any expected credit losses to these portfolios would be immaterial to our financial statements.
18
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Equity Securities
The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:
Three Months EndedSix Months Ended
(MILLIONS)July 3,
2022July 4,
2021July 3,
2022July 4,
2021
Net (gains)/losses recognized during the period on equity securities(a)
$541 $(800)$1,241 $(1,200)
Less: Net (gains)/losses recognized during the period on equity securities sold during the period(68)24 (79)(5)
Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date(b)
$610 $(823)$1,320 $(1,196)
(a)Reported in Other (income)/deductions net. See Note 4.
(b)Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of July 3, 2022, there were cumulative impairments and downward adjustments of $108 million and upward adjustments of $194 million. Impairments, downward and upward adjustments were not significant in the second quarter and first six months of 2022 and 2021.
C. Short-Term Borrowings
Short-term borrowings include:
(MILLIONS)July 3,
2022December 31, 2021
Current portion of long-term debt, principal amount$1,251 $1,636
Other short-term borrowings, principal amount(a)
4,714 605
Total short-term borrowings, principal amount
5,965 2,241
Net fair value adjustments related to hedging and purchase accounting25
Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted
$5,990 $2,241
(a)As of July 3, 2022, primarily includes $3.7 billion related to the Consumer Healthcare JV loan (see Note 2C), and cash collateral (see Note 7F). As of December 31, 2021, primarily includes cash collateral. See Note 7F.
D. Long-Term Debt
The following summarizes the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt:
(MILLIONS)July 3,
2022December 31, 2021
Total long-term debt, principal amount$33,352 $34,948
Net fair value adjustments related to hedging and purchase accounting1,125 1,438
Net unamortized discounts, premiums and debt issuance costs(185)(195)
Other long-term debt2 4
Total long-term debt, carried at historical proceeds, as adjusted$34,294 $36,195
E. Derivative Financial Instruments and Hedging Activities
Foreign Exchange Risk A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. Where foreign exchange risk is not offset by other exposures, we manage our foreign exchange risk principally through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to mitigate the impact on net income as a result of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.
The derivative financial instruments primarily hedge or offset exposures in the euro, U.K. pound, Japanese yen, and Canadian dollar, and include a portion of our forecasted foreign exchange-denominated intercompany inventory sales hedged up to two years. We may seek to protect against possible declines in the reported net investments of our foreign business entities.
Interest Rate Risk Our interest-bearing investments and borrowings are subject to interest rate risk. Depending on market conditions, we may change the profile of our outstanding debt or investments by entering into derivative financial instruments like interest rate swaps, either to hedge or offset the exposure to changes in the fair value of hedged items with fixed interest rates, or to convert variable rate debt or investments to fixed rates. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.
19
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations):